Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2

Sponsor
Novo Nordisk A/S
Study ID
NCT01484262
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
  • insulin — DRUG
    Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.

Study Details

This study is conducted in Europe. The intention of this health service research study is to obtain data from daily routine to evaluate the quality of life and the costs of the disease for patients with type 2 diabetes mellitus.

Key Dates

Start date
Nov 14, 2011
Status verified
Oct 2018
Primary completion
Oct 31, 2014
Completion
Oct 31, 2014

Study Design

Enrollment
1,344 participants (actual)

Arms

  • Arm: Liraglutide
  • Arm: Any insulin

Primary Outcome Measure

Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life) [ Time Frame: At the end of the observational period (52 weeks) ]

Related Studies